Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

Rachel Babij, Jai S Perumal Department of Neurology, Weill Cornell Medical College, New York, NY, USA Abstract: Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Babij R, Perumal JS
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/2993ef1696434324957fe06fda7e50b1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2993ef1696434324957fe06fda7e50b1
record_format dspace
spelling oai:doaj.org-article:2993ef1696434324957fe06fda7e50b12021-12-02T01:18:10ZComparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis1178-2021https://doaj.org/article/2993ef1696434324957fe06fda7e50b12015-05-01T00:00:00Zhttp://www.dovepress.com/comparative-efficacy-of-alemtuzumab-andnbspestablished-treatment-in-th-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Rachel Babij, Jai S Perumal Department of Neurology, Weill Cornell Medical College, New York, NY, USA Abstract: Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B lymphocytes, monocytes, natural killer cells, macrophages, and dendritic cells. Following its administration, a prolonged T-cell lymphopenia results with emergence of a reconstituted immune system that differs in its composition from that pretreatment. In clinical trials, alemtuzumab has shown impressive efficacy with regard to clinical and radiological outcomes in relapsing multiple sclerosis, along with sustained long-term beneficial effects, and it is attractive for its once-yearly administration. Despite this, the occurrence of serious secondary autoimmune disorders, infections, and a potential risk of malignancy necessitates a careful evaluation of risks versus benefits for an individual patient prior to its use. The requirement of patient commitment to the intense mandatory monitoring program is also a factor to be considered when incorporating alemtuzumab into the treatment regimen. Keywords: alemtuzumab, multiple sclerosis, comparative efficacyBabij RPerumal JSDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 1221-1229 (2015)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Babij R
Perumal JS
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
description Rachel Babij, Jai S Perumal Department of Neurology, Weill Cornell Medical College, New York, NY, USA Abstract: Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B lymphocytes, monocytes, natural killer cells, macrophages, and dendritic cells. Following its administration, a prolonged T-cell lymphopenia results with emergence of a reconstituted immune system that differs in its composition from that pretreatment. In clinical trials, alemtuzumab has shown impressive efficacy with regard to clinical and radiological outcomes in relapsing multiple sclerosis, along with sustained long-term beneficial effects, and it is attractive for its once-yearly administration. Despite this, the occurrence of serious secondary autoimmune disorders, infections, and a potential risk of malignancy necessitates a careful evaluation of risks versus benefits for an individual patient prior to its use. The requirement of patient commitment to the intense mandatory monitoring program is also a factor to be considered when incorporating alemtuzumab into the treatment regimen. Keywords: alemtuzumab, multiple sclerosis, comparative efficacy
format article
author Babij R
Perumal JS
author_facet Babij R
Perumal JS
author_sort Babij R
title Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
title_short Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
title_full Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
title_fullStr Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
title_full_unstemmed Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
title_sort comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/2993ef1696434324957fe06fda7e50b1
work_keys_str_mv AT babijr comparativeefficacyofalemtuzumabandnbspestablishedtreatmentinthemanagementofnbspmultiplesclerosis
AT perumaljs comparativeefficacyofalemtuzumabandnbspestablishedtreatmentinthemanagementofnbspmultiplesclerosis
_version_ 1718403128800313344

Ejemplares similares